Rob Hopfner, BSP, PhD, MBA, is an Investment Partner at Bay City Capital and has been with the firm since August 2002. Before joining Bay City Capital, Dr. Hopfner worked in DuPont Pharmaceuticals’ Business Development & Strategic Planning group and at Ag-West Biotech, a Western Canadian seed-stage biotech venture capital firm. Dr. Hopfner focuses on biopharmaceutical investments and is involved in a number of portfolio companies including Altheos, Inc., Dermira, Inc., NextWave Therapeutics, Hyperion Therapeutics, Aciex Therapeutics, and PTC Therapeutics. Dr. Hopfner holds a PhD in Pharmacology and a BS in Pharmacy from the University of Saskatchewan and an MBA with specializations in Entrepreneurship, Finance and Strategy from the University of Chicago Booth School of Business. His biomedical research was focused on vascular and endocrine pharmacology and he completed post-doctoral work at Harvard Medical School. Dr. Hopfner won numerous awards during his research career, including the Governor General of Canada Gold Medal Award in 2000, and published several articles in top medical journals based on his work. Dr. Hopfner started his career as a pharmacist.